Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride

Experimental and Clinical Endocrinology and Diabetes

Volumn 114, Issue 9, 2006, Pages 527-532

  Kann, Peter H ^a   Wascher, T ^b   Zackova, V ^c   Moeller, J ^d   Medding, J ^d   Szocs, A ^e   Mokan, M ^f   Mrevlje, F ^g   Regulski, M ^h  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

^c Diabetologicke Centrum   (Czech Republic)

^d Novo Nordisk Pharma GmbH   (Germany)

^e Károlyi Sándor Hospital   (Hungary)

^f UK a Martinskej Fakultnej Nemocnice   (Slovakia)

^g UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^h Department of Internal Diseases   (Poland)

Author keywords

Biphasic insulin aspart 30 plus metformin; Insulin glargine plus glimepiride; Insulin initiation; Premixed insulin analog; Type 2 diabetes mellitus

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; METFORMIN;

ADULT; AGED; ARTICLE; BACKACHE; BILE DUCT STONE; BLADDER NECK STENOSIS; BODY WEIGHT; CLINICAL TRIAL; CONCUSSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROCOLITIS; FACIAL NERVE PARALYSIS; FEMALE; GASTRITIS; HEART FAILURE; HUMAN; HYPERTHYROIDISM; HYPOGLYCEMIA; HYPOGLYCEMIC COMA; INJECTION SITE ERYTHEMA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MALLORY WEISS SYNDROME; MENTAL DEFICIENCY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS NECROSIS; PERIPHERAL EDEMA; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; TREATMENT DURATION; URETER STONE; URINARY TRACT INFECTION; VERTEBRA FRACTURE; WEIGHT CHANGE;

AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 33845317568     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-949655     Document Type: Article

References (18)

1. Alvarsson M, Sundkvist G, Lager I, Henriccson M, Berntorp K, Fernqvist-Forbes E, Steen L, Westermark G, Westermark P, Orn T, Grill V. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003; 26: 2231-2237
2. European Diabetes Policy Group A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730
3. Fritsche A, Schweitzer MA, Haring HU, 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-959
4. Howey DC, Bowsher RR, Brunelle RL, Wordsworth JR [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402
5. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type 11 diabetes mellitus. Diabetologia 1999; 42: 406-412
6. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycemic control in patients with type 2 diabetes. Diabet Med 2005; 22: 374-381
7. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH, Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 2034-2044
8. Monnier L, Lapinski H, Colette C. Contributions of fasting and post-prandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003; 26: 881-885
9. Mudaliar S, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR. Insulin aspart (B28 Asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999; 22: 1501-1506
10. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 1231-1239
11. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A, INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265
12. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086
13. Rosenstock J. Basal insulin supplementation in type 2 diabetes: refining the tactics. Am J Med 2004; 116 (Suppl. 3A): 10S-16S
14. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2015
15. UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-883
16. UKPDS Group UK Prospective Diabetes Study 16: overview of six years' therapy of type 2 diabetes-a progressive disease. Diabetes 1995; 44: 1249-1258
17. World Medical Association Revising the declaration of Helsinki. Bull Med Ethics 2000; 158: 9-11
18. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR, U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336